Research question
Kidney disease is a global health problem with high mortality and socioeconomic burden. Metabolic disorders are increasingly recognized as a key driver of the onset and progression of kidney disease. However, reliable metabolic indicators remain lacking for predicting the development of kidney disease.
Objectives
First, we will investigate how metabolic disorders influence the onset and progression of kidney disease, focusing on conditions such as acute kidney injury, chronic kidney disease, diabetic kidney disease, chronic glomerulopathies, and nephrotic syndrome. Next, we aim to elucidate the complex interplay between metabolic disorders and environmental elements, such as lifestyle behaviors (smoking, diet, and physical activity etc.) Lastly, we seek to identify clinically significant metabolic markers and intervention strategies that can facilitate early detection, precise risk stratification, and personalized treatment approaches, ultimately improving patient outcomes and mitigating the global burden of kidney disease.
Scientific rationale
Emerging evidence suggests that metabolic indicators, such as obesity, insulin resistance, diabetes, metabolic syndrome, dyslipidemia and hyperuricemia, play a crucial role in kidney disease progression. However, most existing studies rely on cross-sectional designs or small sample sizes, limiting causal inference and generalizability. Additionally, the interplay between metabolic disorders and environmental factors remains poorly understood. Thus, we will integrate multi-omics approaches (i.e., proteomics and metabolomics) with comprehensive epidemiological data to identify novel metabolic risk factors and biomarkers associated with kidney disease. Our study will analyze large-scale multi-omics datasets alongside clinical and environmental information to uncover new metabolic indicators linked to the onset and progression of kidney disease, providing evidence for early detection and precision medicine.
